Comparison · NCT01675661-sae
NAC Plus CM vs Placebo Plus CM: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. NAC Plus CM vs Placebo Plus CM: serious adverse events. Trial comparisons, record NCT01675661-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01675661-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00654 | 0.00115 | 0.0361 | wilson | |
| Risk in group 2 | 0.0403 | 0.0186 | 0.0851 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0337 | -0.0788 | 0.00292 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.162 | 0.0198 | 1.33 | log | |
| Odds ratio, group 1 over group 2 | 0.157 | 0.0186 | 1.32 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on NAC Plus CM than on Placebo Plus CM | 29.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | NAC Plus CM | N-acetylcysteine (NAC) plus Contingency Management (CM)~N-Acetylcysteine: Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions. | 1 | 153 | EG000 |
| Group 2 | Placebo Plus CM | Placebo plus Contingency Management (CM)~Placebo: Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions. | 6 | 149 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Evaluation of adverse events began after informed consent and continued at each weekly visit until the final 13 week follow up visit for all participants.
Source ClinicalTrials.gov
Trial
- Title
- Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment
- NCT number
- NCT01675661
- Phases
- PHASE3
- Conditions
- Cannabis Dependence
- Interventions
- N-Acetylcysteine, Placebo
- Lead sponsor
- Medical University of South Carolina
- Results first posted
- 2017-03-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01675661?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01675661-sae